Delta Genomics completes asset sale of genotyping services to Neogen Canada Inc.

July 18, 2019

On January 2, 2019, Delta Genomics Centre (“Delta”) sold its genotyping services in an asset sale to Neogen Canada Inc. (“Neogen Canada”), a subsidiary of Neogen Corporation (“Neogen”) (NASDAQ: NEOG). With the acquisition, Delta’s laboratory operations will continue under Neogen Canada and become Neogen’s fifth animal genomics laboratory worldwide. The acquisition will help ensure more affordable genomics services to drive greater adoption of genomic technologies throughout the Canadian livestock industry.

Delta is a national, not-for-profit genomics company that services members of both the livestock industry and livestock research community. Delta provides services by leveraging its extensive research capabilities, connections and resources to help develop valuable tools to assist its customers in making strategic management decisions.

Miller Thomson advised Delta with respect to this transaction with a team that includes Joseph Yurkovich (Corporate Tax) and Mark Siry (Transactions & Leasing).